AbobotulinumtoxinA: A 25-Year History

Gary D Monheit, Andy Pickett, Gary D Monheit, Andy Pickett

Abstract

During the late 1960s and early 1970s, Alan Scott showed that intramuscular injections of botulinum toxin (BoNT) corrected nonaccommodative strabismus without resorting to surgery. The UK doctors who trained with Scott soon realized the significant potential offered by BoNT type A as a therapeutic option for several difficult-to-treat diseases. This led to a collaboration between these pioneering clinicians and the Centre for Applied Microbiology and Research at Porton Down, United Kingdom, and, in turn, to the development and commercialization of abobotulinumtoxinA as Dysport (Dystonia/Porton Down; Ipsen Biopharm Ltd., Wrexham, UK). Dysport was approved in Europe for the treatment of specific dystonias in December 1990 and now has marketing authorizations in 75 countries. Since then, the use of BoNT in therapeutic and aesthetic indications has grown year-on-year, and continues to expand well beyond Scott's initial aim. For example, ongoing trials are assessing potential new indications for BoNT-A, including acne and psoriasis. Furthermore, a growing number of other BoNT products, often termed "biosimilars," together with innovative formulations of well-established BoNT types, are likely to reach the market over the next few years. This review focuses on the history of Dysport to mark the 25th anniversary of its first launch in the United Kingdom.

© 2017 The American Society for Aesthetic Plastic Surgery, Inc.

References

    1. Scott AB, Rosenbaum A, Collins CC. Pharmacologic weakening of extraocular muscles. Invest Ophthalmol. 1973;12(12):924-927.
    1. Orsini M, Leite MA, Chung TM, et al. Botulinum neurotoxin type A in neurology: update. Neurol Int. 2015;7(2):5886.
    1. Chen S. Clinical uses of botulinum neurotoxins: current indications, limitations and future developments. Toxins (Basel). 2012;4(10):913-939.
    1. Zanchi M, Favot F, Bizzarini M, Piai M, Donini M, Sedona P. Botulinum toxin type-A for the treatment of inverse psoriasis. J Eur Acad Dermatol Venereol. 2008;22(4):431-436.
    1. Gilbert E, Ward NL. Efficacy of botulinum neurotoxin type A for treating recalcitrant plaque psoriasis. J Drugs Dermatol. 2014;13(11):1407-1408.
    1. Saber M, Brassard D, Benohanian A. Inverse psoriasis and hyperhidrosis of the axillae responding to botulinum toxin type A. Arch Dermatol. 2011;147(5):629-630.
    1. Min P, Xi W, Grassetti L, et al. Sebum production alteration after botulinum toxin type A injections for the treatment of forehead rhytides: a prospective randomized double-blind dose-comparative clinical investigation. Aesthet Surg J. 2015;35(5):600-610.
    1. Shah AR. Use of intradermal botulinum toxin to reduce sebum production and facial pore size. J Drugs Dermatol. 2008;7(9):847-850.
    1. Stephen JM, Urquhart DW, van Arkel RJ, et al. The use of sonographically guided botulinum toxin type A (Dysport) injections into the tensor fasciae latae for the treatment of lateral patellofemoral overload syndrome. Am J Sports Med. 2016;44(5):1195-1202.
    1. Dorizas A, Krueger N, Sadick NS. Aesthetic uses of the botulinum toxin. Dermatol Clin. 2014;32(1):23-36.
    1. Cosmetic Surgery National Data Bank Statistics. Aesthet Surg J. 2016;36(Suppl 1):1-29.
    1. Erbguth FJ. From poison to remedy: the chequered history of botulinum toxin. J Neural Transm (Vienna). 2008;115(4):559-565.
    1. Haas LF. Atropa belladonna (deadly nightshade). J Neurol Neurosurg Psychiatry. 1995;58(3):283.
    1. Erbguth FJ, Naumann M. Historical aspects of botulinum toxin: Justinus Kerner (1786-1862) and the “sausage poison”. Neurology. 1999;53(8):1850-1853.
    1. Ting PT, Freiman A. The story of Clostridium botulinum: from food poisoning to Botox. Clin Med (Lond). 2004;4(3):258-261.
    1. Kerner J. Travel shadows: translated from the German and edited by Harold B Segel. Newcastle upon Tyne: Cambridge Scholars Publishing; 2014.
    1. Ministry of Health and Long-Term Care. Botulism Accessed February 24, 2016.
    1. Pellett S. Learning from the past: historical aspects of bacterial toxins as pharmaceuticals. Curr Opin Microbiol. 2012;15(3):292-299.
    1. Brieger L, Fraenkel C. Untersuchungen über Bakteriengifte, Berlin. Klin Wochenschr. 1890;27:231-246, 268-271.
    1. Winslow CE, Broadhurst J, Buchanan RE, Krumwiede C, Rogers LA, Smith GH. The families and genera of the bacteria: preliminary report of the committee of the society of American bacteriologists on characterization and classification of bacterial types. J Bacteriol. 1917;2(5):505-566.
    1. Bengtson IA. Studies on organisms concerned as causative factors in botulism. Hygiene Laboratory Bulletin 136. Washington, DC: US Public Health Service; 1924.
    1. Arnon SS, Werner SB, Faber HK, Farr WH. Infant botulism in 1931. Discovery of a misclassified case. Am J Dis Child. 1979;133(6):580-582.
    1. HALL IC. The occurrence of Bacillus botulinus, types A and B, in accidental wounds. J Bacteriol. 1945;50:213-217.
    1. Leuchs J. Beiträge zur Kenntnis des Toxins und antitoxins des Bacillus botulinus. Z Hyg Infektionskr. 1910;65(1):55-84.
    1. Burke GS. Notes on Bacillus botulinus. J Bacteriol. 1919;4(5):555-570.1.
    1. Collins MD, East AK. Phylogeny and taxonomy of the food-borne pathogen Clostridium botulinum and its neurotoxins. J Appl Microbiol. 1998;84(1):5-17.
    1. Rossetto O, Pirazzini M, Montecucco C. Botulinum neurotoxins: genetic, structural and mechanistic insights. Nat Rev Microbiol. 2014;12(8):535-549.
    1. Eleopra R, Montecucco C, Devigili G, et al. Botulinum neurotoxin serotype D is poorly effective in humans: an in vivo electrophysiological study. Clin Neurophysiol. 2013;124(5):999-1004.
    1. Wagner Sommer E, Sommer H, Meyer KF. The purification of botulinum toxin. J Infect Dis. 1926;39(5):345-350.
    1. Scott AB. Botulinum toxin injection of eye muscles to correct strabismus. Trans Am Ophthalmol Soc. 1981;79:734-770.
    1. Conrad Berens, 1889–1963. Br J Ophthalmol. 1963;47(6):383-384.
    1. Pickett A. Historical aspects of botulinum toxin used clinically: part I: is that the right serotype? Botulinum J. 2013;2(3/4):176.
    1. Schantz EJ, Johnson EA. Properties and use of botulinum toxin and other microbial neurotoxins in medicine. Microbiol Rev. 1992;56(1):80-99.
    1. Scott AB. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Ophthalmology. 1980;87(10):1044-1049.
    1. Scott AB. Botulinum toxin treatment of strabismus. Am Orthopt J. 1985;35:28-29.
    1. Ney JP, Joseph KR. Neurologic uses of botulinum neurotoxin type A. Neuropsychiatr Dis Treat. 2007;3(6):785-798.
    1. Allergan. History and development Accessed March 1, 2016.
    1. Moore T. John Lee obituary Guardian On-line 2010 Accessed February 24, 2016.
    1. Elston JS, Lee JP, Powell CM, Hogg C, Clark P. Treatment of strabismus in adults with botulinum toxin A. Br J Ophthalmol. 1985;69(10):718-724.
    1. Hambleton P, Capel B, Bailey N, et al. Production, purification and toxoiding of Clostridium Botulinum type a toxin A2. In: Lewis G, ed. Biomedical Aspects of Botulism. New York, NY: Academic Press; 1981:247-260.
    1. Van den Bergh P, Francart J, Mourin S, Kollmann P, Laterre EC. Five-year experience in the treatment of focal movement disorders with low-dose Dysport botulinum toxin. Muscle Nerve. 1995;18(7):720-729.
    1. Poewe W, Deuschl G, Nebe A, et al. What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport. German Dystonia Study Group. J Neurol Neurosurg Psychiatry. 1998;64(1):13-17.
    1. Odergren T, Hjaltason H, Kaakkola S, et al. A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia. J Neurol Neurosurg Psychiatry. 1998;64(1):6-12.
    1. Ascher B, Zakine B, Kestemont P, Baspeyras M, Bougara A, Santini J. A multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar lines. J Am Acad Dermatol. 2004;51(2):223-233.
    1. Carruthers JA, Lowe NJ, Menter MA, et al. ; BOTOX Glabellar Lines I Study Group. A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. J Am Acad Dermatol. 2002;46(6):840-849.
    1. Kane MA, Gold MH, Coleman WP, 3rd, et al. A randomized, double-blind trial to investigate the equivalence of IncobotulinumtoxinA and OnabotulinumtoxinA for glabellar frown lines. Dermatol Surg. 2015;41(11):1310-1319.
    1. Michaels BM, Csank GA, Ryb GE, Eko FN, Rubin A. Prospective randomized comparison of onabotulinumtoxinA (Botox) and abobotulinumtoxinA (Dysport) in the treatment of forehead, glabellar, and periorbital wrinkles. Aesthet Surg J. 2012;32(1):96-102.
    1. Karsai S, Adrian R, Hammes S, Thimm J, Raulin C. A randomized double-blind study of the effect of Botox and Dysport/Reloxin on forehead wrinkles and electromyographic activity. Arch Dermatol. 2007;143(11):1447-1449.
    1. Carruthers A, Carruthers J. History of the cosmetic use of Botulinum A exotoxin. Dermatol Surg. 1998;24(11):1168-1170.
    1. Blitzer A, Brin MF, Keen MS, Aviv JE. Botulinum toxin for the treatment of hyperfunctional lines of the face. Arch Otolaryngol Head Neck Surg. 1993;119(9):1018-1022.
    1. Clark RP, Berris CE. Botulinum toxin: a treatment for facial asymmetry caused by facial nerve paralysis. Plast Reconstr Surg. 1989;84(2):353-355.
    1. Clark RP, Berris CE. Botulinum toxin: a treatment for facial asymmetry caused by facial nerve paralysis. Plast Reconstr Surg. 2005;115(2):573-574.
    1. Carruthers JD, Carruthers JA. Treatment of glabellar frown lines with C. botulinum-A exotoxin. J Dermatol Surg Oncol. 1992;18(1):17-21.
    1. Hankins CL, Strimling R, Rogers GS. Botulinum A toxin for glabellar wrinkles. Dose and response. Dermatol Surg. 1998;24(11):1181-1183.
    1. Dewandre L, Voloshchenko I, Trembach A. Pilot study to compare the efficacy and the duration of activity of Dysport vs Botox in classical esthetic indications (forehead, glabella, crow’s feet). Le Journal de Médecine Esthétique et de Chirurgie Dermatologique. 2003;30:101-107.
    1. Rzany B, Ascher B, Fratila A, Monheit GD, Talarico S, Sterry W. Efficacy and safety of 3- and 5-injection patterns (30 and 50 U) of botulinum toxin A (Dysport) for the treatment of wrinkles in the glabella and the central forehead region. Arch Dermatol. 2006;142(3):320-326.
    1. Kamin W, Staubach P, Klär-Hlawatsch B, Erdnüss F, Knuf M. Anaphylaxis after vaccination due to hypersensitivity to gelatin. Klin Padiatr. 2006;218(2):92-94.
    1. Careta MF, Delgado L, Patriota R. Report of allergic reaction after application of botulinum toxin. Aesthet Surg J. 2015;35(5):NP102-NP105.
    1. Kim BJ, Kwon HH, Park SY, et al. Double-blind, randomized non-inferiority trial of a novel botulinum toxin A processed from the strain CBFC26, compared with onabotulinumtoxin A in the treatment of glabellar lines. J Eur Acad Dermatol Venereol. 2014;28(12):1761-1767.
    1. Wadhwa M, Knezevic I, Kang HN, Thorpe R. Immunogenicity assessment of biotherapeutic products: An overview of assays and their utility. Biologicals. 2015;43(5):298-306.
    1. Pickett A, O’Keeffe R, Panjwani N. The protein load of therapeutic botulinum toxins. Eur J Neurol. 2007;14(4):e11.
    1. Brin MF, James C, Maltman J. Botulinum toxin type A products are not interchangeable: a review of the evidence. Biologics. 2014;8:227-241.
    1. Pickett A. Historical aspects of botulinum toxin used clinically: Part II: overcoming resistance. Botulinum J. 2015;3(1):34-40.
    1. Ludlow CL, Hallett M, Rhew K, et al. Therapeutic use of type F botulinum toxin. N Engl J Med. 1992;326(5):349-350.
    1. Alster TS, Lupton JR. Botulinum toxin type B for dynamic glabellar rhytides refractory to botulinum toxin type A. Dermatol Surg. 2003;29(5):516-518.
    1. Sadick NS. Prospective open-label study of botulinum toxin type B (Myobloc) at doses of 2400 and 3000 U for the treatment of glabellar wrinkles. Dermatol Surg. 2003;29(5):501-507; discussion 507.
    1. Carruthers A, Carruthers J, Flynn TC, Leong MS. Dose-finding, safety, and tolerability study of botulinum toxin type B for the treatment of hyperfunctional glabellar lines. Dermatol Surg. 2007;33(1 Spec No):S60-S68.
    1. Eleopra R, Tugnoli V, Quatrale R, Rossetto O, Montecucco C, Dressler D. Clinical use of non-A botulinum toxins: botulinum toxin type C and botulinum toxin type F. Neurotox Res. 2006;9(2-3):127-131.
    1. Galderma. Press release: Galderma initiates U.S. study of novel muscle relaxant for aesthetic dermatology and cosmetic surgery. October 06, 2014 Accessed March 14, 2016.
    1. Glogau RG. Topically applied botulinum toxin type A for the treatment of primary axillary hyperhidrosis: results of a randomized, blinded, vehicle-controlled study. Dermatol Surg. 2007;33(1 Spec No):S76-S80.
    1. Brandt F, O’Connell C, Cazzaniga A, Waugh JM. Efficacy and safety evaluation of a novel botulinum toxin topical gel for the treatment of moderate to severe lateral canthal lines. Dermatol Surg. 2010;36(Suppl 4):2111-2118.
    1. Pickett A. The different botulinum toxins from around the world currently available for clinical use. In: Benedetto A, ed Botulinum Toxins in Aesthetic Clinical Practice. 3rd edition. Boca Raton, Florida: Taylor & Francis, in press.
    1. Revance Reports Results for RT001 Topical Phase 3 trial for lateral canthal lines [Press release] Accessed July 25, 2016.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir